**Patient Details**

- **DOB:** 01/11/1990
- **Age:** 027/00/27
- **Gender:** F

**Specimen Details**

- **Date collected:** 02/07/2017
- **Date entered:** 02/08/2017
- **Date reported:** 00/00/0000

**Physician Details**

- **ID:**
- **NPI:**

---

**Ordered Items**

Galectin-3 with BNP

**Galectin-3 with BNP**

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galectin-3</td>
<td>&lt;22.2</td>
<td></td>
<td>ng/mL</td>
<td>&lt;22.2</td>
<td>01</td>
</tr>
</tbody>
</table>

Reference range of <22.2 ng/mL applies to population without known heart disease.
Galectin-3 is NOT a marker of cardiac distress or decompensation.
Galectin-3 is a marker of fibrosis and adverse remodeling resulting in a more progressive form of chronic heart failure. The BGM Galectin-3 assay results should be interpreted in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.
* Galectin-3 levels less than or equal to 17.8 ng/mL - LOWER risk of adverse outcomes including mortality or hospitalization.
* Galectin-3 levels greater than 17.8 ng/mL - HIGHER risk of adverse outcomes including mortality or hospitalization.
* Galectin-3 levels between 17.8 ng/mL and 25.9 ng/mL should be interpreted with caution because these values lie within the reference range.

Additional Considerations
- Approximately 30% of NYHA class II/III outpatient population were found to have elevated galectin-3 levels (>17.8 ng/mL). [1]
- Elevated galectin-3 is found in similar percentages of patients with systolic dysfunction and preserved ejection fraction. [1]
- Galectin-3 shows modest correlations with clinical variables, including Age (slightly higher levels in older subjects), Gender (women have slightly higher values) certain co-morbidities (diabetes and atrial fibrillation), and NYHA classification. [2]
- Once elevated galectin-3 levels are generally stable over time. [2]
- Drugs effective in the management of patients with heart failure often fail to reduce levels of galectin-3 and galectin-3 levels should not be used to guide therapy.
* Galectin-3 testing was cleared by the FDA for use in
patients with chronic heart failure only. [1]

(1) BG Galectin-3 Product Label
(2) de Boer, R; Lok, D; Jaarsma, T, et al. Value of Plasma Galectin-3 levels in Heart Failure with Reduced and Preserved Ejection Fraction. Ann Medicine, 2011; 43(1):60-68.

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-Type Natriuretic Peptide</td>
<td>52.2</td>
<td></td>
<td>pg/mL</td>
<td>0.0 - 100.0</td>
<td>01 BN LabCorp Burlington</td>
</tr>
</tbody>
</table>

01 BN LabCorp Burlington
1447 York Court, Burlington, NC 27215-3361
Dir: William F Hancock, MD

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762
ABNORMAL REPORT

Galectin-3 with BNP

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galectin-3</td>
<td>&lt;22.2</td>
<td></td>
<td>ng/mL</td>
<td>&lt;22.2</td>
<td>01</td>
</tr>
</tbody>
</table>

- Reference range of <22.2 ng/mL applies to population without known heart disease.
- Galectin-3 is NOT a marker of cardiac distress or decompensation.
- Galectin-3 is a marker of fibrosis and adverse remodeling resulting in a more progressive form of chronic heart failure. The BGM Galectin-3 assay results should be interpreted in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.
- * Galectin-3 levels less than or equal to 17.8 ng/mL - LOWER risk of adverse outcomes including mortality or hospitalization.
- * Galectin-3 levels greater than 17.8 ng/mL - HIGHER risk of adverse outcomes including mortality or hospitalization.
- * Galectin-3 levels between 17.8 ng/mL and 25.9 ng/mL should be interpreted with caution because these values lie within the reference range.

Additional Considerations
- Approximately 30% of NYHA class II/III outpatient population were found to have elevated galectin-3 levels (>17.8 ng/mL). [1]
- Elevated galectin-3 is found in similar percentages of patients with systolic dysfunction and preserved ejection fraction. [1]
- Galectin-3 shows modest correlations with clinical variables, including Age (slightly higher levels in older subjects), Gender (women have slightly higher values) certain co-morbidities (diabetes and atrial fibrillation), and NYHA classification. [2]
- Once elevated galectin-3 levels are generally stable over time. [2]
- Drugs effective in the management of patients with heart failure often fail to reduce levels of galectin-3 and galectin-3 levels should not be used to guide therapy.
- * Galectin-3 testing was cleared by the FDA for use in
### TESTS

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-Type Natriuretic Peptide</td>
<td>220.9</td>
<td>High</td>
<td>pg/mL</td>
<td>0.0 - 100.0</td>
<td>01 BN</td>
</tr>
</tbody>
</table>

1. de Boer, R; Lok, D; Jaarsma, T, et al. Value of Plasma Galectin-3 levels in Heart Failure with Reduced and Preserved Ejection Fraction. Ann Medicine, 2011; 43(1):60-68.

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762